The global robot-assisted surgical medical device market accounted for USD 6.34 billion in 2023 and is expected to reach at USD 19.24 billion by 2034 with a CAGR of 10.62% during the forecast period 2024-2034. The market will grow as a result of factors such as the rising prevalence of chronic diseases, rising acceptance and awareness, favorable reimbursement policies, and rising demand for minimally invasive surgeries.
Compared to open procedures, robot-assisted surgeries usually require fewer incisions. Patients experience less trauma, lose less blood, and recover more quickly as a result. Robot-assisted surgical devices are becoming more and more popular as a result of the increased demand for minimally invasive surgical treatments. For instance, Medrobotics stated in June 2024 that its first head and neck surgery procedures using the Flex Robotic System had been completed successfully in Canada.
By application, the cardiovascular surgery segment accounted for the highest revenue-grossing segment in the global robot-assisted surgical medical device market in 2023 owing to the increased use of robot-assisted methods in complex cardiac surgeries and the global increase in the incidence of cardiovascular diseases. For instance, Medtronic reported in December 2022 that the first patient had been enrolled in the Hugo robotic-assisted surgery (RAS) system clinical trial in the United States. Dr. Michael R. Abern of Durham, North Carolina's Duke University Hospital executed a robotically assisted prostatectomy. Additionally, the neurosurgery segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for precision and minimally invasive procedures in neurosurgical interventions and advancements in robot-assisted technologies tailored for neurosurgery.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global robot-assisted surgical medical device market in 2023 owing to the increasing adoption of robot-assisted surgical systems by hospitals to enhance surgical outcomes and improve patient care. For instance, Accuray's VOLO Optimized Dynamic WaveArc for the CyberKnife S7 System, which improves radiation therapy treatments, was cleared by the FDA in April 2024. Additionally, the ambulatory surgery centers segment is estimated to grow at the fastest CAGR during the forecast period owing to the rising demand for outpatient surgical procedures, advancements in minimally invasive techniques, and the expansion of ambulatory surgery centers globally.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high adoption rate of advanced medical technologies, Favorable reimbursement policies, and well-established healthcare infrastructure in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing investments in healthcare infrastructure, rising disposable income, and growing awareness about advanced medical treatments in the Asia Pacific region. For instance, Johnson & Johnson subsidiary Auris Health, Inc. announced in May 2022 that the FDA had cleared their Monarch robotic surgery system. The kidney stone removal procedures can be carried out with the robot thanks to the system. The first and only multispecialty, adaptable robotic solution for bronchoscopy and urology is the Monarch robotic surgical system.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Compared to open procedures, robot-assisted surgeries usually require fewer incisions. Patients experience less trauma, lose less blood, and recover more quickly as a result. Robot-assisted surgical devices are becoming more and more popular as a result of the increased demand for minimally invasive surgical treatments. For instance, Medrobotics stated in June 2024 that its first head and neck surgery procedures using the Flex Robotic System had been completed successfully in Canada.
By application, the cardiovascular surgery segment accounted for the highest revenue-grossing segment in the global robot-assisted surgical medical device market in 2023 owing to the increased use of robot-assisted methods in complex cardiac surgeries and the global increase in the incidence of cardiovascular diseases. For instance, Medtronic reported in December 2022 that the first patient had been enrolled in the Hugo robotic-assisted surgery (RAS) system clinical trial in the United States. Dr. Michael R. Abern of Durham, North Carolina's Duke University Hospital executed a robotically assisted prostatectomy. Additionally, the neurosurgery segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing demand for precision and minimally invasive procedures in neurosurgical interventions and advancements in robot-assisted technologies tailored for neurosurgery.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global robot-assisted surgical medical device market in 2023 owing to the increasing adoption of robot-assisted surgical systems by hospitals to enhance surgical outcomes and improve patient care. For instance, Accuray's VOLO Optimized Dynamic WaveArc for the CyberKnife S7 System, which improves radiation therapy treatments, was cleared by the FDA in April 2024. Additionally, the ambulatory surgery centers segment is estimated to grow at the fastest CAGR during the forecast period owing to the rising demand for outpatient surgical procedures, advancements in minimally invasive techniques, and the expansion of ambulatory surgery centers globally.
North American region is anticipated to have the highest revenue share during the forecast period owing to the high adoption rate of advanced medical technologies, Favorable reimbursement policies, and well-established healthcare infrastructure in the North American region. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing investments in healthcare infrastructure, rising disposable income, and growing awareness about advanced medical treatments in the Asia Pacific region. For instance, Johnson & Johnson subsidiary Auris Health, Inc. announced in May 2022 that the FDA had cleared their Monarch robotic surgery system. The kidney stone removal procedures can be carried out with the robot thanks to the system. The first and only multispecialty, adaptable robotic solution for bronchoscopy and urology is the Monarch robotic surgical system.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Application, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement
Segmentation: Robot-Assisted Surgical Medical Device Market Report 2023 - 2034
Robot-Assisted Surgical Medical Device Market Analysis & Forecast by Application 2023 - 2034 (Revenue USD Bn)
- Gynecology Surgery
- Cardiovascular Surgery
- Neurosurgery
- Orthopedic Surgery
- Urology Surgery
- Other
Robot-Assisted Surgical Medical Device Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
- Hospitals
- Ambulatory Surgery Centers
- Others
Robot-Assisted Surgical Medical Device Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Robot-Assisted Surgical Medical Device Market: Application Estimates & Trend Analysis
8. Robot-Assisted Surgical Medical Device Market: End-User Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Robot-Assisted Surgical Medical Device Market
11. Europe Global Robot-Assisted Surgical Medical Device Market
12. Asia Pacific Global Robot-Assisted Surgical Medical Device Market
13. Latin America Global Robot-Assisted Surgical Medical Device Market
14. MEA Global Robot-Assisted Surgical Medical Device Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Intuitive Surgical Inc.
- Medtronic plc
- Stryker Corporation
- Zimmer Biomet Holdings Inc.
- Smith & Nephew plc
- TransEnterix Surgical Inc.
- Mazor Robotics Ltd. (acquired by Medtronic)
- Verb Surgical Inc. (joint venture between Verily
- an Alphabet company
- and Johnson & Johnson)
- Auris Health Inc. (acquired by Johnson & Johnson)
- Titan Medical Inc.
- Accuray Incorporated
- Renishaw plc
- CMR Surgical Ltd.
- Medrobotics Corporation.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | October 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 6.34 Billion |
| Forecasted Market Value ( USD | $ 19.24 Billion |
| Compound Annual Growth Rate | 10.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 16 |
